More sensitive HIT cell therapy shows promise against solid cancers

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now found that a new type of cell therapy—HIT cells, a cousin to CAR T with enhanced sensitivity—overcomes a major obstacle to treating solid tumors with cell therapy and can completely eliminate kidney, pancreatic, and ovarian cancers in mice. The research appears in the journal Science.